SEC Form SC 13G/A filed by Foghorn Therapeutics Inc. (Amendment)

2/9/23 10:59:20 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FHTX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 FOGHORN THERAPEUTICS INC COMMON STOCK Cusip #344174107 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #344174107 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,117,227 Item 6: 0 Item 7: 3,117,394 Item 8: 0 Item 9: 3,117,394 Item 11: 7.457% Item 12: HC Cusip #344174107 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 3,117,394 Item 8: 0 Item 9: 3,117,394 Item 11: 7.457% Item 12: IN Item 1(a). Name of Issuer: FOGHORN THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 500 TECHNOLOGY SQUARE, SUITE 700 CAMBRIDGE, MA 02139 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 344174107 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 3,117,394 (b) Percent of Class: 7.457% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 3,117,394 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of FOGHORN THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of FOGHORN THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of FOGHORN THERAPEUTICS INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $FHTX alert in real time by email

Recent Analyst Ratings for

$FHTX

Date	Price Target	Rating	Analyst
4/23/2025	$9.00	Mkt Outperform	Citizens JMP
1/30/2025	$10.00	Buy	B. Riley Securities
9/3/2024	$18.00	Buy	Jefferies
8/19/2024	$20.00	Outperform	Evercore ISI
3/28/2023	$10.00	Buy	BofA Securities
1/5/2023	$20.00	Outperform	BMO Capital Markets
12/15/2021	$23.00 → $26.00	Overweight	Morgan Stanley
11/22/2021	$25.00	Buy	HC Wainwright & Co.

More analyst ratings

SEC Form SC 13G/A filed by Foghorn Therapeutics Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for
$FHTX

$FHTX
Leadership Updates

Live Leadership Updates

Ted Myles Joins Cellarity as Chief Executive Officer

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

$FHTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

B. Riley Securities initiated coverage on Foghorn Therapeutics with a new price target

Jefferies initiated coverage on Foghorn Therapeutics with a new price target

$FHTX
Press Releases

Fastest customizable press release news feed in the world

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update

Ted Myles Joins Cellarity as Chief Executive Officer

$FHTX
Financials

Live finance-specific insights

$FHTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

$FHTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting

Amendment: SEC Form SC 13G/A filed by Foghorn Therapeutics Inc.

SEC Form SC 13G filed by Foghorn Therapeutics Inc.